Top in cardiology: Next-generation artificial heart, methamphetamine-related heart failure
Doctors at Duke University Hospital performed the first North American implantation of a next-generation total artificial heart. The 39-year-old patient is recovering well after the 8-hour procedure, doctors said.
The announcement was the top story in cardiology last week.
Another top story revealed a rapid rise in methamphetamine-related heart failure (HF) hospitalizations. Researchers reported that 4.12% of HF hospitalizations between 2008 and 2018 were related to methamphetamine use.
Read these and more top stories in cardiology below:
First North American patient implanted with next-generation total artificial heart
Duke University and Carmat announced that doctors at Duke University Hospital performed the first North American implantation of a next-generation total artificial heart. Read more.
Methamphetamine-related HF hospitalization ‘insidious yet rapidly growing’
Methamphetamine-related HF hospitalizations and their costs increased at an alarming rate compared with all HF hospitalization from 2008 to 2018, researchers reported. Read more.
Regional, ethnic disparities may exist with empagliflozin efficacy in HF
The effects of the SGLT2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) varied depending on region and racial/ethnic group, with the most benefit observed in those with the highest ratios of HF hospitalization to cardiovascular death, according to EMPEROR-Reduced trial data. Read more.
Stage 2 hypertension increases risk for maternal, fetal, neonatal adverse outcomes
Severe stage 2 hypertension, but not elevated BP and stage 1 hypertension, was associated with maternal, fetal or neonatal mortality or morbidity in low-resource settings, according to new research published in The Lancet Global Health. Read more.
Cardiac cells can be grown in space
Beating cardiomyocytes were successfully grown from stem cells in space, which could have future implications for cardiac research. Read more.